Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Skin grafts on mice can cause an immune response leading to hair loss, useful for studying human hair loss conditions.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

No single treatment is consistently effective for alopecia areata, and more research is needed.

Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.

Restoring hair bulb immune privilege is crucial for managing alopecia areata.

Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

The Lexington LaserComb helped regrow hair in mice with a condition similar to human hair loss.

The 308-nm Excimer laser is effective and safe for treating patchy alopecia areata in children.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

More research is needed to understand alopecia areata severity.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.

Alopecia Areata causes emotional stress and stigma, but those with severe hair loss may adapt better.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.

Oral minoxidil helps hair regrowth in 80% of alopecia patients, but only 18% see cosmetic improvement.

Topical minoxidil effectively and safely treats extensive alopecia areata but doesn't change its course.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.